Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348619 · ClinicalTrials.gov registry record · Phase 3
"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 174
- Enrollment target
NCT02348619 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 174 participants.
The verdict
NCT02348619, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 174 participants
- Enrollment target
Study Summary
This trial is a 6-week, double-blind, placebo-controlled, randomized-withdrawal, multicenter study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.
Interventions
- DRUG JZP-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348619
The ClinicalTrials.gov registry entry for NCT02348619 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JZP-110 is the first listed.
NCT02348619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348619 about?
NCT02348619 is a clinical study titled ""Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"". This trial is a 6-week, double-blind, placebo-controlled, randomized-withdrawal, multicenter study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.
What is the current status of trial NCT02348619?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 174 participants. The study started on 2015-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02348619?
The interventions under investigation include: JZP-110 (DRUG).
Who is sponsoring clinical trial NCT02348619?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.